<DOC>
	<DOCNO>NCT00031707</DOCNO>
	<brief_summary>RATIONALE : Megestrol /or omega-3 fatty acid-enriched nutritional supplement may improve cancer-related weight loss lack appetite . It yet know whether megestrol alone , omega-3 fatty acid-enriched nutritional supplement alone , combination effective treat cancer-related weight loss loss appetite . PURPOSE : Randomized phase III trial compare effectiveness megestrol without omega-3 fatty acid-enriched nutritional supplement omega-3 fatty acid-enriched nutritional supplement alone treat patient cancer-related weight loss lack appetite .</brief_summary>
	<brief_title>Comparison Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement Treating Patients With Cancer-Related Weight Loss Lack Appetite</brief_title>
	<detailed_description>OBJECTIVES : - Compare appetite-stimulating property megestrol vs eicosapentaenoic acid-enriched nutritional supplement v , term patient weight , rate weight change , appetite , patient cancer-related cachexia anorexia . - Determine effect regimens nausea vomit patient . - Assess quality life patient treat regimen . - Determine toxic effect regimens patient . - Compare overall survival patient treat regimen . - Correlate interleukin-6 concentration change appetite weight change patient treat regimen . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord primary cancer ( lung vs gastrointestinal v ) , severity weight loss past 2 month ( less 10 pound vs 10 pound ) , plan concurrent chemotherapy ( yes v ) , age ( 50 vs 50 ) , prognosis ( good v bad vs unsure ) . Patients randomize 1 3 treatment arm .</detailed_description>
	<mesh_term>Anorexia</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven cancer brain , breast , ovarian , endometrial , prostate cancer Compelling clinical evidence cancer allow tissue sample unobtainable Considered incurable available therapy At least 5 pound weight loss within past 2 month ( exclude perioperative weight loss ) and/or estimate caloric intake less 20 cal/kg daily Weight loss must perceive problem patient Potential weight gain must consider beneficial attend physician No history primary brain cancer brain metastases No clinical evidence ascites PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Cardiovascular : No poorly control congestive heart failure No poorly control hypertension No history thromboembolic disease Other : Not pregnant nursing Fertile patient must use effective contraception Alert mentally competent Able reliably take oral medication No known mechanical obstruction alimentary tract , malabsorption , intractable vomiting ( 5 episode per week ) No diabetes require insulin Diabetes require oral hypoglycemic agent diet control allow PRIOR CONCURRENT THERAPY : Chemotherapy : Concurrent chemotherapy allow Endocrine therapy : At least 1 month since prior adrenal steroid , androgen , progestational agent , appetite stimulant ( e.g. , dronabinol ) No concurrent adrenal steroid , androgen , progestational agent , appetite stimulant ( e.g. , dronabinol ) Inhalant , topical , optical steroid allow Shortterm dexamethasone antiemetic chemotherapy allow Radiotherapy : Concurrent radiotherapy allow Other : No tube feed parenteral nutrition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>anorexia</keyword>
	<keyword>cachexia</keyword>
</DOC>